Annual Total Expenses
$121.49 M
-$71.72 M-37.12%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual total expenses is currently $121.49 million, with the most recent change of -$71.72 million (-37.12%) on 31 December 2023. During the last 3 years, it has fallen by -$21.68 million (-15.14%). LGND annual total expenses is now -37.12% below its all-time high of $193.21 million, reached on 31 December 2022.LGND Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$40.86 M
+$6.72 M+19.67%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly total expenses is currently $40.86 million, with the most recent change of +$6.72 million (+19.67%) on 30 September 2024. Over the past year, it has increased by +$8.95 million (+28.03%). LGND quarterly total expenses is now -46.59% below its all-time high of $76.50 million, reached on 31 March 2004.LGND Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -37.1% | +28.0% |
| 3 y3 years | -15.1% | -16.8% |
| 5 y5 years | +38.5% | +36.3% |
LGND Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -37.1% | at low | -42.0% | +5169.1% |
| 5 y | 5 years | -37.1% | +38.5% | -42.0% | +5169.1% |
| alltime | all time | -37.1% | +307.9% | -46.6% | +176.3% |
Ligand Pharmaceuticals Incorporated Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $40.86 M(+19.7%) |
| June 2024 | - | $34.14 M(+22.0%) |
| Mar 2024 | - | $27.99 M(-11.0%) |
| Dec 2023 | $121.49 M(-37.1%) | $31.46 M(-1.4%) |
| Sept 2023 | - | $31.91 M(+12.6%) |
| June 2023 | - | $28.35 M(-4.8%) |
| Mar 2023 | - | $29.77 M(-57.8%) |
| Dec 2022 | $193.21 M(+40.3%) | $70.48 M(+50.3%) |
| Sept 2022 | - | $46.88 M(+13.1%) |
| June 2022 | - | $41.46 M(+20.6%) |
| Mar 2022 | - | $34.38 M(-4365.9%) |
| Dec 2021 | $137.69 M(-3.8%) | -$806.00 K(-101.6%) |
| Sept 2021 | - | $49.13 M(+26.2%) |
| June 2021 | - | $38.94 M(-22.8%) |
| Mar 2021 | - | $50.44 M(+21.9%) |
| Dec 2020 | $143.18 M(+13.6%) | $41.38 M(+8.6%) |
| Sept 2020 | - | $38.10 M(+11.0%) |
| June 2020 | - | $34.32 M(+16.8%) |
| Mar 2020 | - | $29.37 M(-21.0%) |
| Dec 2019 | $126.00 M(+43.6%) | $37.18 M(+24.1%) |
| Sept 2019 | - | $29.97 M(+2.9%) |
| June 2019 | - | $29.12 M(-2.1%) |
| Mar 2019 | - | $29.74 M(+12.5%) |
| Dec 2018 | $87.73 M(+20.1%) | $26.44 M(+18.6%) |
| Sept 2018 | - | $22.30 M(+12.2%) |
| June 2018 | - | $19.87 M(+3.9%) |
| Mar 2018 | - | $19.12 M(-13.6%) |
| Dec 2017 | $73.03 M(+12.2%) | $22.11 M(+31.0%) |
| Sept 2017 | - | $16.88 M(+12.7%) |
| June 2017 | - | $14.98 M(-21.4%) |
| Mar 2017 | - | $19.05 M(+1.2%) |
| Dec 2016 | $65.09 M(+46.0%) | $18.83 M(+16.6%) |
| Sept 2016 | - | $16.15 M(+3.9%) |
| June 2016 | - | $15.55 M(+6.9%) |
| Mar 2016 | - | $14.55 M(+32.7%) |
| Dec 2015 | $44.59 M(+1.7%) | $10.96 M(+25.2%) |
| Sept 2015 | - | $8.76 M(-36.7%) |
| June 2015 | - | $13.84 M(+25.4%) |
| Mar 2015 | - | $11.03 M(-13.8%) |
| Dec 2014 | $43.83 M(+32.9%) | $12.80 M(+13.7%) |
| Sept 2014 | - | $11.26 M(+23.5%) |
| June 2014 | - | $9.11 M(-14.5%) |
| Mar 2014 | - | $10.65 M(+31.4%) |
| Dec 2013 | $32.99 M(+9.3%) | $8.11 M(-16.5%) |
| Sept 2013 | - | $9.71 M(+28.7%) |
| June 2013 | - | $7.54 M(-1.2%) |
| Mar 2013 | - | $7.63 M(-15.3%) |
| Dec 2012 | $30.17 M(+1.3%) | $9.01 M(+17.9%) |
| Sept 2012 | - | $7.64 M(+6.9%) |
| June 2012 | - | $7.14 M(+11.8%) |
| Mar 2012 | - | $6.39 M(-19.9%) |
| Dec 2011 | $29.78 M(-14.7%) | $7.98 M(+11.8%) |
| Sept 2011 | - | $7.14 M(-18.1%) |
| June 2011 | - | $8.71 M(+46.3%) |
| Mar 2011 | - | $5.96 M(-163.9%) |
| Dec 2010 | $34.90 M(-50.4%) | -$9.32 M(-139.0%) |
| Sept 2010 | - | $23.90 M(+141.6%) |
| June 2010 | - | $9.89 M(-5.0%) |
| Mar 2010 | - | $10.41 M(-69.9%) |
| Dec 2009 | $70.32 M | $34.57 M(+385.1%) |
| Sept 2009 | - | $7.13 M(-39.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2009 | - | $11.81 M(-31.7%) |
| Mar 2009 | - | $17.28 M(+9.8%) |
| Dec 2008 | $54.55 M(-27.3%) | $15.74 M(+35.7%) |
| Sept 2008 | - | $11.60 M(+11.2%) |
| June 2008 | - | $10.44 M(-39.5%) |
| Mar 2008 | - | $17.26 M(+9.4%) |
| Dec 2007 | $75.03 M(-8.6%) | $15.78 M(+11.1%) |
| Sept 2007 | - | $14.20 M(-10.0%) |
| June 2007 | - | $15.78 M(-46.1%) |
| Mar 2007 | - | $29.28 M(+25.9%) |
| Dec 2006 | $82.06 M(+52.4%) | $23.26 M(+3.6%) |
| Sept 2006 | - | $22.45 M(+17.4%) |
| June 2006 | - | $19.12 M(+11.0%) |
| Mar 2006 | - | $17.23 M(-132.2%) |
| Dec 2005 | $53.84 M(-57.8%) | -$53.53 M(-246.3%) |
| Sept 2005 | - | $36.59 M(-30.0%) |
| June 2005 | - | $52.31 M(-0.9%) |
| Mar 2005 | - | $52.76 M(-331.5%) |
| Dec 2004 | $127.49 M(-17.8%) | -$22.78 M(-147.9%) |
| Sept 2004 | - | $47.54 M(-7.5%) |
| June 2004 | - | $51.40 M(-32.8%) |
| Mar 2004 | - | $76.50 M(+83.1%) |
| Dec 2003 | $155.13 M(+34.2%) | $41.77 M(+5.8%) |
| Sept 2003 | - | $39.48 M(+3.4%) |
| June 2003 | - | $38.20 M(+7.0%) |
| Mar 2003 | - | $35.69 M(+28.8%) |
| Dec 2002 | $115.62 M(+16.2%) | $27.70 M(-13.6%) |
| Sept 2002 | - | $32.05 M(+11.9%) |
| June 2002 | - | $28.64 M(+5.2%) |
| Mar 2002 | - | $27.23 M(+8.1%) |
| Dec 2001 | $99.48 M(+5.8%) | $25.19 M(+6.1%) |
| Sept 2001 | - | $23.73 M(-5.6%) |
| June 2001 | - | $25.15 M(-1.0%) |
| Mar 2001 | - | $25.40 M(+9.3%) |
| Dec 2000 | $93.99 M(-8.0%) | $23.25 M(-3.3%) |
| Sept 2000 | - | $24.03 M(-1.3%) |
| June 2000 | - | $24.35 M(+8.8%) |
| Mar 2000 | - | $22.37 M(-23.1%) |
| Dec 1999 | $102.19 M(+17.1%) | $29.09 M(+16.8%) |
| Sept 1999 | - | $24.90 M(-1.2%) |
| June 1999 | - | $25.20 M(+9.6%) |
| Mar 1999 | - | $23.00 M(-18.4%) |
| Dec 1998 | $87.30 M(+5.8%) | $28.20 M(+35.6%) |
| Sept 1998 | - | $20.80 M(+1.0%) |
| June 1998 | - | $20.60 M(+16.4%) |
| Mar 1998 | - | $17.70 M(-25.3%) |
| Dec 1997 | $82.50 M(+18.4%) | $23.70 M(+15.6%) |
| Sept 1997 | - | $20.50 M(+6.2%) |
| June 1997 | - | $19.30 M(+2.1%) |
| Mar 1997 | - | $18.90 M(-6.4%) |
| Dec 1996 | $69.70 M(+41.1%) | $20.20 M(+18.1%) |
| Sept 1996 | - | $17.10 M(-1.7%) |
| June 1996 | - | $17.40 M(+16.8%) |
| Mar 1996 | - | $14.90 M(-2.6%) |
| Dec 1995 | $49.40 M(+44.4%) | $15.30 M(+7.0%) |
| Sept 1995 | - | $14.30 M(+64.4%) |
| Mar 1995 | - | $8.70 M(-9.4%) |
| Dec 1994 | $34.20 M | $9.60 M(+12.9%) |
| Sept 1994 | - | $8.50 M(+3.7%) |
| June 1994 | - | $8.20 M(+3.8%) |
| Mar 1994 | - | $7.90 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual total expenses?
- What is the all time high annual total expenses for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual total expenses year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly total expenses?
- What is the all time high quarterly total expenses for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly total expenses year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual total expenses?
The current annual total expenses of LGND is $121.49 M
What is the all time high annual total expenses for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual total expenses is $193.21 M
What is Ligand Pharmaceuticals Incorporated annual total expenses year-on-year change?
Over the past year, LGND annual total expenses has changed by -$71.72 M (-37.12%)
What is Ligand Pharmaceuticals Incorporated quarterly total expenses?
The current quarterly total expenses of LGND is $40.86 M
What is the all time high quarterly total expenses for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly total expenses is $76.50 M
What is Ligand Pharmaceuticals Incorporated quarterly total expenses year-on-year change?
Over the past year, LGND quarterly total expenses has changed by +$8.95 M (+28.03%)